Detalhe da pesquisa
1.
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Cancer Immunol Immunother
; 72(9): 2991-3002, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289256